Even with inhibition of the PI3K–AKT pathway, somatic mutations in the MEK–ERK cascade can provide an escape mechanism, as observed in cancers resistant to anti-HER2 TKIs like tucatinib. The gene discussed is ERBB2; the disease is cancer.